Ken Griffin Cerevel Therapeutics Holdings, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $8.65 Million - $9.49 Million	222,000 Added 2018.18%	233,000 $9.53 Million
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $862,568 - $912,997	-21,100 Reduced 65.73%	11,000 $464,000
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $263,510 - $551,720	13,000 Added 68.06%	32,100 $1.36 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $342,394 - $539,279	-16,900 Reduced 46.94%	19,100 $416,000
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $528,190 - $781,898	-22,100 Reduced 38.04%	36,000 $1.14 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $702,856 - $1.09 Million	30,800 Added 112.82%	58,100 $1.42 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $453,765 - $572,084	-17,900 Reduced 39.6%	27,300 $861,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $395,250 - $642,010	15,500 Added 52.19%	45,200 $1.28 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.